
News|Articles|January 27, 2005
Warning Letter
Warning Letter
Advertisement
In a 7 January
As is typical in these warnings, the agency voicedconcerns that Essential is compounding not for individual patients butfor third-party resale, and that the compounded drugs duplicateapproved products in dosage and concentration.
Douglas McCormick
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Why Oral Solid Dosage Validation Is a Business Continuity Function, Not Just a Compliance Requirement
2
Technology Transfer: Success Drivers and Obstacles Explained
3
Managing Global Trial Supply Risk: Expert Insights
4
How to Vet Importer of Record Partners for Clinical Trials
5


